CA2198379A1 - Fibroblastes pour le traitement des troubles musculaires - Google Patents
Fibroblastes pour le traitement des troubles musculairesInfo
- Publication number
- CA2198379A1 CA2198379A1 CA002198379A CA2198379A CA2198379A1 CA 2198379 A1 CA2198379 A1 CA 2198379A1 CA 002198379 A CA002198379 A CA 002198379A CA 2198379 A CA2198379 A CA 2198379A CA 2198379 A1 CA2198379 A1 CA 2198379A1
- Authority
- CA
- Canada
- Prior art keywords
- muscle
- cells
- dystrophin
- fibroblast cells
- fibroblasts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 90
- 208000021642 Muscular disease Diseases 0.000 title abstract description 7
- 238000011282 treatment Methods 0.000 title description 16
- 210000003205 muscle Anatomy 0.000 claims abstract description 145
- 210000004027 cell Anatomy 0.000 claims abstract description 107
- 230000002500 effect on skin Effects 0.000 claims abstract description 57
- 108010069091 Dystrophin Proteins 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 201000006938 muscular dystrophy Diseases 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 2
- 102000001039 Dystrophin Human genes 0.000 abstract description 43
- 210000000663 muscle cell Anatomy 0.000 abstract description 19
- 230000004927 fusion Effects 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 5
- 102000008934 Muscle Proteins Human genes 0.000 abstract 1
- 108010074084 Muscle Proteins Proteins 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 34
- 210000003491 skin Anatomy 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 210000003098 myoblast Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 230000001114 myogenic effect Effects 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000001177 retroviral effect Effects 0.000 description 10
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010044467 Isoenzymes Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003328 fibroblastic effect Effects 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- -1 PBS + 2mM MgC12 Chemical compound 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000001964 muscle biopsy Methods 0.000 description 2
- 210000003130 muscle precursor cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 101150069452 z gene Proteins 0.000 description 2
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- 101150033248 AME1 gene Proteins 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 239000004429 Calibre Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010019393 Fibrin Foam Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001053945 Mus musculus Dystrophin Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 102100036640 Myosin-10 Human genes 0.000 description 1
- 101710115163 Myosin-10 Proteins 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 101150058817 RRT1 gene Proteins 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229930185229 antidesmin Natural products 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- WHLPIOPUASGRQN-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C WHLPIOPUASGRQN-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 101150015424 dmd gene Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000034272 protein filaments Human genes 0.000 description 1
- 108091005974 protein filaments Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
On traite des affections musculaires telles que la dystrophie musculaire de Duchenne en introduisant dans le muscle des fibroblastes dermiques (qui peuvent être ceux du patient lui-même). La fusion in vivo des cellules donatrices entre elles convertit celles-ci en cellules musculaires, lesquelles expriment les produits des gènes spécifiques du muscle, tels que la dystrophine ainsi que d'autres protéines musculaires. Les fibroblastes donneurs peuvent contenir de l'ADN spécifique du muscle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9419048A GB9419048D0 (en) | 1994-09-20 | 1994-09-20 | Treatment of muscular disorders |
| GB9419048.5 | 1994-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2198379A1 true CA2198379A1 (fr) | 1996-03-28 |
Family
ID=10761695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002198379A Abandoned CA2198379A1 (fr) | 1994-09-20 | 1995-09-15 | Fibroblastes pour le traitement des troubles musculaires |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0783568A1 (fr) |
| JP (1) | JPH10505756A (fr) |
| AU (1) | AU694957B2 (fr) |
| CA (1) | CA2198379A1 (fr) |
| GB (2) | GB9419048D0 (fr) |
| WO (1) | WO1996009373A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9715085D0 (en) | 1997-07-18 | 1997-09-24 | Jahoda Amanda J | Gene therapy vehicle |
| IT1296439B1 (it) * | 1997-11-14 | 1999-06-25 | San Raffaele Centro Fond | Precursori miogenici modificati geneticamente e loro uso in terapia genica e cellulare |
| IT1299201B1 (it) * | 1998-05-08 | 2000-02-29 | San Raffaele Centro Fond | Fibroblasti modificati geneticamente e loro uso |
| WO2016201182A1 (fr) * | 2015-06-11 | 2016-12-15 | The Board Of Trustees Of The University Of Illinios | Cellules chimériques de dystrophie musculaire et méthode de traitement des dystrophies musculaires |
| EP3564362A4 (fr) * | 2016-12-28 | 2020-07-08 | Kyoto Prefectural Public University Corporation | Cellules de muscle squelettique et leur procédé d'induction |
| WO2020243543A1 (fr) * | 2019-05-31 | 2020-12-03 | Figene, Llc | Thérapie par fibroblastes pour le traitement de la dystrophie musculaire de duchenne |
| WO2022016184A1 (fr) * | 2020-07-14 | 2022-01-20 | Figene, Llc | Augmentation de l'activité thérapeutique de fibroblastes par blocage et/ou inhibition du complément |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219740A (en) * | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| EP0633318A1 (fr) * | 1987-09-11 | 1995-01-11 | Whitehead Institute For Biomedical Research | Fibroblastes transduits et leurs applications |
| JP3244696B2 (ja) * | 1989-06-13 | 2002-01-07 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー | ヒト筋肉細胞の単離、増殖および分化 |
| US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
| AU7312891A (en) * | 1990-02-12 | 1991-09-03 | Board Of Regents, The University Of Texas System | Satellite cell proliferation in adult skeletal muscle |
| US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| AU678158B2 (en) * | 1992-04-10 | 1997-05-22 | Fox Chase Cancer Center | Transcription control element for increasing gene expression in myoblasts |
| WO1993024151A1 (fr) * | 1992-05-29 | 1993-12-09 | The General Hospital Corporation | Injection de myoblastes par voie arterielle |
-
1994
- 1994-09-20 GB GB9419048A patent/GB9419048D0/en active Pending
-
1995
- 1995-09-15 WO PCT/GB1995/002187 patent/WO1996009373A1/fr not_active Ceased
- 1995-09-15 AU AU34816/95A patent/AU694957B2/en not_active Ceased
- 1995-09-15 CA CA002198379A patent/CA2198379A1/fr not_active Abandoned
- 1995-09-15 JP JP8510668A patent/JPH10505756A/ja active Pending
- 1995-09-15 EP EP95931336A patent/EP0783568A1/fr not_active Ceased
- 1995-09-15 GB GB9518887A patent/GB2293604B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996009373A1 (fr) | 1996-03-28 |
| EP0783568A1 (fr) | 1997-07-16 |
| GB9419048D0 (en) | 1994-11-09 |
| AU694957B2 (en) | 1998-08-06 |
| JPH10505756A (ja) | 1998-06-09 |
| GB2293604A (en) | 1996-04-03 |
| GB2293604B (en) | 1996-09-11 |
| AU3481695A (en) | 1996-04-09 |
| GB9518887D0 (en) | 1995-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4562816B2 (ja) | 心筋再生のための間葉幹細胞の使用法および組成物 | |
| TWI278518B (en) | Methods and compositions for the differentiation of human preadipocytes into adipocytes | |
| AU784618B2 (en) | Cells capable of differentiating into heart muscle cells | |
| US20020031501A1 (en) | Cardiomyocytes for heart muscles damaged in heart attacks | |
| US20010051148A1 (en) | Compositions comprising preconditioned myoblasts having enhanced fusion properties | |
| JPH07503121A (ja) | 内皮細胞の遺伝的変性 | |
| Cheng et al. | Influence of human platelet lysate on extracellular matrix deposition and cellular characteristics in adipose-derived stem cell sheets | |
| JP2000500641A (ja) | 哺乳類宿主の結合組織を処置するための遺伝子移入 | |
| Franz et al. | X-linked dilated cardiomyopathy | |
| Tang et al. | The enhancement of endothelial cell therapy for angiogenesis in hindlimb ischemia using hyaluronan | |
| JPH05500601A (ja) | ヒト筋肉細胞の単離、増殖および分化 | |
| CA2198379A1 (fr) | Fibroblastes pour le traitement des troubles musculaires | |
| Jebran et al. | Transmural myocardial repair with engineered heart muscle in a rat model of heterotopic heart transplantation–A proof-of-concept study | |
| KR20190015153A (ko) | 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물 | |
| JP7679034B2 (ja) | 医薬用組成物 | |
| CN114377034A (zh) | 一种用于关节炎治疗的生物制剂及其制备方法和应用 | |
| Kinoshita et al. | Mechanism of increasing dystrophin-positive myofibers by myoblast transplantation: study using mdx/β-galactosidase transgenic mice | |
| CN116785501A (zh) | 促进心脏组织修复的modRNA转染改造的细胞及其应用 | |
| CN1688701A (zh) | 成肌细胞转移治疗心力衰竭的机理 | |
| EP3194574B1 (fr) | Procédé de culture de cellules souches in vitro | |
| CN111484978A (zh) | miR-140-5p过表达修饰的人脐带间充质干细胞、其治疗制剂、制备方法和应用 | |
| CN115089610A (zh) | 骨骼干细胞在制备用于治疗骨关节炎的产品中的应用 | |
| US8221740B2 (en) | Side population cells in cardiac repair | |
| CN1969039A (zh) | 组织材料和肌肉来源的基质 | |
| Hagiwara et al. | Dystrophin-positive muscle fibers following C2 myoblast transplantation into mdx nude mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |